非酒精性脂肪肝治疗的分子靶点

Molecular target for treatment of non-alcoholic fatty liver disease

非酒精性脂肪肝(non-alcoholic fatty liver disease,NAFLD)的发病率日益增高,迄今为止尚没有确切有效的治疗措施。目前的研究主要针对NAFLD及其代谢障碍的分子机制,包括核转录因子孕烷X受体(pregnane X receptor,PXR)、叉头蛋白O1(forkhead box protein O1,FOXO1)、类法尼醇X受体(farnesoid X receptor,FXR)、过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptors,PPARs)、甲状腺激素受体(thyroid hormone receptor,THR)、腺苷酸活化蛋白激酶(AMP-activated protein kinase,AMPK)、p53、核因子E2相关因子2(nuclear erythroid 2-related factor 2,Nrf2)、线粒体、大麻素受体和胆汁酸受体等。本文主要就这些分子机制作一综述,探讨这些靶点的潜在治疗价值。

Non-alcoholic fatty liver disease（NAFLD） is on a rise and until now there has been no effective treatment. Recent researches have mainly focused on molecular mechanisms of NAFLD and metabolic disorders, involving studies on pregnane X receptor （PXR）, forkhead box protein O1 （FOXO1）, farnesoid X receptor （FXR）, peroxisome proliferator-activated receptors （PPARs）, thyroid hormone receptor （THR）, AMP-activated protein kinase （AMPK）, p53, nuclear erythroid 2-related factor 2 （Nrf2）, mitochondria, cannabinoid receptors, and bile-acid receptor. This review focused on these molecular mechanisms and discussed the potential values of the above targets for treatment of NAFLD.